Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
For each presentation, an archived replay will be accessible in the Investors section of the Keros website at for up to 90 days following the conclusion of each event.LEXINGTON, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that Keros' Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will present at the following healthcare conferences:
麻州列剋星敦，2024年11月26日（環球新聞通訊社）-- Keros Therapeutics, Inc.（"Keros"或"公司"）（納斯達克：KROS），是一家臨床階段的生物製藥公司，專注於開發和商業化新型治療方法，旨在治療與轉化生長因子-beta（"TGF-ß"）蛋白家族功能失調信號相關的各種患者。今天，Keros的董事長兼首席執行官Jasbir S. Seehra博士宣佈將在以下醫療健康會議上進行演講：
Piper Sandler 36th Annual Healthcare Conference
派傑投資第36屆醫療保健年會
- Date and Time: Tuesday, December 3, 2024 at 10:30 a.m. Eastern time
- Link:
-
Format: Fireside Chat Presentation
- 日期和時間：2024年12月3日，星期二，東部時間上午10:30
- 鏈接：
- 形式：爐邊對話演講
7th Annual Evercore HealthCONx Conference
第七屆evercore HealthCONx大會
- Date and Time: Wednesday, December 4, 2024 at 3:00 p.m. Eastern time
- Link:
-
Format: Fireside Chat Presentation
- 日期和時間：2024年12月4日星期三下午3:00（東部時間）
- 鏈接：
- 形式：爐邊對話演講
For each presentation, an archived replay will be accessible in the Investors section of the Keros website at for up to 90 days following the conclusion of each event.
每個演示後，歸檔重播將在Keros網站的投資者部分可獲取，持續90天，直到每個活動結束。
About Keros Therapeutics, Inc.
關於Keros Therapeutics，Inc.
Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins. The Company is a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including blood, bone, skeletal muscle, adipose and heart tissue. By leveraging this understanding, Keros has discovered and is developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Keros' lead product candidate, elritercept (KER-050), is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with myelofibrosis. Keros' second product candidate, cibotercept (KER-012), is being developed for the treatment of pulmonary arterial hypertension for the treatment of cardiovascular disorders. Keros' third product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases.
Keros是一家臨床階段的生物製藥公司，專注於開發和商業化新型療法，以治療與TGF-ß蛋白家族信號功能失調相關的各種患者。該公司在理解TGF-ß蛋白家族的作用方面處於領先地位，這些蛋白是多種組織（包括血液、骨骼、骨骼肌、脂肪和心臟組織）的生長、修復和維護的主要調控因子。通過利用這種理解，Keros發現並正在開發具有潛在重要和可能改變疾病進程的蛋白質療法。Keros的主要產品候選藥物elritercept (KER-050)正在開發用於治療低血細胞計數或細胞減少症，包括貧血和血小板減少症，適用於患有骨髓增生異常綜合症和骨髓纖維化的患者。Keros的第二個產品候選藥物cibotercept (KER-012)正在開發用於治療肺動脈高壓，以應對心血管疾病。Keros的第三個產品候選藥物KER-065正在開發用於治療肥胖和神經肌肉疾病。
Investor Contact:
Justin Frantz
jfrantz@kerostx.com
617-221-6042
投資者聯繫人：
Justin Frantz
jfrantz@kerostx.com
617-221-6042
譯文內容由第三人軟體翻譯。
